ASGCT dispatch: In vivo CAR-T is everywhere, but still preclinical

It’s a crucial moment for the cell and gene therapy field. At the American Society of Gene & Cell Therapy’s annual meeting, several trends emerged: In vivo CAR-T is everywhere, CRISPR comes for Alzheimer’s and FDA officials took the stage. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing:…

Source: Endpoints News